3-(methanesulfonylamino)rhodanine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(methanesulfonylamino)rhodanine
• 英文别名: 3-(Methanesulfonylamino)-4-oxo-2-thionothiazolidine；N-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)methanesulfonamide
• 化学式: C₄H₆N₂O₃S₃
• 分子量: 226.301
• InChiKey: HQAJGRQRGHPWMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(methanesulfonylamino)rhodanine 、 3,4-二氯苯甲醛 在 sodium acetate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以55%的产率得到5-(3,4-Dichlorobenzylidene)-3-(methanesulfonylamino)-4-oxo-2-thionothiazolidine
  参考文献：
  名称：

  SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase

  摘要：

  Novel non-nucleoside inhibitors of the HCV RNA polymerase (NS5b) with sub-micromolar biochemical potency have been identified which are selective for the inhibition of HCV NS5b over other polymerases. The structures of the complexes formed between several of these inhibitors and HCV NS5b were determined by X-ray crystallography, and the inhibitors were found to bind in an allosteric binding site separate from the active site. Structure-activity relationships and structural studies have identified the mechanism of action for compounds in this series, several of which possess drug-like properties, as unique, reversible, covalent inhibitors of HCV NS5b.

  DOI：

  10.1021/jm050859x
• 作为产物：
  描述：

  甲磺酰肼 、 双(羧甲基)三硫代碳酸盐 以 水 为溶剂， 反应 20.0h， 以57%的产率得到3-(methanesulfonylamino)rhodanine
  参考文献：
  名称：

  SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase

  摘要：

  Novel non-nucleoside inhibitors of the HCV RNA polymerase (NS5b) with sub-micromolar biochemical potency have been identified which are selective for the inhibition of HCV NS5b over other polymerases. The structures of the complexes formed between several of these inhibitors and HCV NS5b were determined by X-ray crystallography, and the inhibitors were found to bind in an allosteric binding site separate from the active site. Structure-activity relationships and structural studies have identified the mechanism of action for compounds in this series, several of which possess drug-like properties, as unique, reversible, covalent inhibitors of HCV NS5b.

  DOI：

  10.1021/jm050859x

文献信息

• NS5B HCV polymerase inhibitors
  申请人：Tularik Inc.

  公开号：US20020142290A1

  公开（公告）日：2002-10-03

  Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.

  本发明提供了在治疗和预防某些病毒感染和相关疾病中有用的化合物、组合物和方法。特别地，本发明的化合物抑制病毒RNA聚合酶的活性。该方法特别适用于治疗由丙型肝炎病毒感染引起的疾病。
• NS5B HVC polymerase inhibitors
  申请人：Tularik Inc.

  公开号：US06727267B2

  公开（公告）日：2004-04-27

  Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.

  本发明提供了在治疗和预防某些病毒感染和相关疾病方面有用的化合物、组合物和方法。特别是，本发明的化合物抑制病毒RNA聚合酶的活性。本方法在治疗由丙型肝炎病毒感染引起的疾病方面特别有用。
• SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase
  作者：Jay P. Powers、Derek E. Piper、Yang Li、Veronica Mayorga、John Anzola、James M. Chen、Juan C. Jaen、Gary Lee、Jinqian Liu、M. Greg Peterson、George R. Tonn、Qiuping Ye、Nigel P. C. Walker、Zhulun Wang

  DOI：10.1021/jm050859x

  日期：2006.2.1

  Novel non-nucleoside inhibitors of the HCV RNA polymerase (NS5b) with sub-micromolar biochemical potency have been identified which are selective for the inhibition of HCV NS5b over other polymerases. The structures of the complexes formed between several of these inhibitors and HCV NS5b were determined by X-ray crystallography, and the inhibitors were found to bind in an allosteric binding site separate from the active site. Structure-activity relationships and structural studies have identified the mechanism of action for compounds in this series, several of which possess drug-like properties, as unique, reversible, covalent inhibitors of HCV NS5b.